PubMed Health⌕ Search

PubMed · 3978552

Recurrence rates for colorectal polyps.

Abstract

Of 276 patients who underwent an initial colonoscopic polypectomy for adenomatous polyps over a 45-month period, 118 subsequently had one or more repeat screening colonoscopies. The mean follow-up time was 26 months with an overall polyp recurrence rate of 30%. Analysis of these data retrospectively suggests that the bulk of the recurrences occurred within the first year. Increasing age was found to be a significant risk factor for polyp recurrence. Asymptomatic recurrence of adenomatous polyps detectable by colonoscopy is a common occurrence in postpolypectomy patients. Prospective studies utilizing colonoscopy as a screening tool are needed to establish a rational screening policy for this high-risk group.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A I Neugut, C M Johnsen, K A Forde, M R Treat. 1985-04-01. Recurrence rates for colorectal polyps.. https://doi.org/10.1002/1097-0142(19850401)55%3A7%3C1586%3A%3Aaid-cncr2820550729%3E3.0.co%3B2-i

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Crohn's disease.

Crohn's disease is a relapsing systemic inflammatory disease, mainly affecting the gastrointestinal tract with extraintestinal manifestations and associated immune disorders. Genome wide association studies identified susceptibility loci that--triggered by environmental factors--result in a disturbed innate (ie, disturbed intestinal barrier, Paneth cell dysfunction, endoplasmic reticulum stress, defective unfolded protein response and autophagy, impaired recognition of microbes by pattern recognition receptors, such as nucleotide binding domain and Toll like receptors on dendritic cells and macrophages) and adaptive (ie, imbalance of effector and regulatory T cells and cytokines, migration and retention of leukocytes) immune response towards a diminished diversity of commensal microbiota. We discuss the epidemiology, immunobiology, amd natural history of Crohn's disease; describe new treatment goals and risk stratification of patients; and provide an evidence based rational approach to diagnosis (ie, work-up algorithm, new imaging methods [ie, enhanced endoscopy, ultrasound, MRI and CT] and biomarkers), management, evolving therapeutic targets (ie, integrins, chemokine receptors, cell-based and stem-cell-based therapies), prevention, and surveillance.

Colonic Diseases↗